$1.5996
0.0046[0.29%]
At close: Apr 25
$1.5996
0[0.00%]
PreMarket: 5:53PM EDT
aTyr Pharma
(NASDAQ:LIFE)aTyr Pharma Stock (NASDAQ:LIFE), Analyst Ratings, Price Targets, Predictions
aTyr Pharma Inc has a consensus price target of $17.25, established from looking at the 27 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, HC Wainwright & Co., and HC Wainwright & Co. on March 15, 2024, March 15, 2024, and February 21, 2024. With an average price target of $28.67 between RBC Capital, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 1692.11% upside for aTyr Pharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
HC Wainwright & Co.
Piper Sandler
Oppenheimer
Roth MKM
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for aTyr Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/15/2024 | LIFE | Buy Now | aTyr Pharma | $1.60 | 900.25% | RBC Capital | Gregory Renza | $19 → $16 | Maintains | Outperform | Get Alert |
| 03/15/2024 | LIFE | Buy Now | aTyr Pharma | $1.60 | 2088.05% | HC Wainwright & Co. | Joseph Pantginis | → $35 | Reiterates | Buy → Buy | Get Alert |
| 02/21/2024 | LIFE | Buy Now | aTyr Pharma | $1.60 | 2088.05% | HC Wainwright & Co. | Joseph Pantginis | → $35 | Reiterates | Buy → Buy | Get Alert |
| 09/21/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | 2088.05% | HC Wainwright & Co. | Joseph Pantginis | → $35 | Reiterates | Buy → Buy | Get Alert |
| 09/14/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | 2088.05% | HC Wainwright & Co. | Joseph Pantginis | → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | 2088.05% | HC Wainwright & Co. | Joseph Pantginis | → $35 | Reiterates | Buy → Buy | Get Alert |
| 07/21/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | 1150.31% | Piper Sandler | Edward Tenthoff | $13 → $20 | Maintains | Overweight | Get Alert |
| 07/05/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | — | Oppenheimer | Hartaj Singh | — | Downgrade | Outperform → Perform | Get Alert |
| 05/23/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | 2088.05% | HC Wainwright & Co. | Joseph Pantginis | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | 1087.8% | RBC Capital | Gregory Renza | → $19 | Reiterates | → Outperform | Get Alert |
| 04/11/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | 712.7% | Piper Sandler | Edward Tenthoff | $9 → $13 | Maintains | Overweight | Get Alert |
| 03/10/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | 1087.8% | RBC Capital | Gregory Renza | → $19 | Reiterates | → Outperform | Get Alert |
| 03/10/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | 2088.05% | HC Wainwright & Co. | Joseph Pantginis | → $35 | Reiterates | → Buy | Get Alert |
| 03/06/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | 462.64% | Roth MKM | Kumaraguru Raja | → $9 | Reinstates | → Buy | Get Alert |
| 03/02/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | 1087.8% | RBC Capital | Gregory Renza | $20 → $19 | Maintains | Outperform | Get Alert |
| 02/07/2023 | LIFE | Buy Now | aTyr Pharma | $1.60 | 2088.05% | HC Wainwright & Co. | Joseph Pantginis | → $35 | Reiterates | → Buy | Get Alert |
| 08/16/2022 | LIFE | Buy Now | aTyr Pharma | $1.60 | 775.22% | Piper Sandler | Edward Tenthoff | $11 → $14 | Maintains | Overweight | Get Alert |
| 07/21/2022 | LIFE | Buy Now | aTyr Pharma | $1.60 | 2088.05% | HC Wainwright & Co. | Joseph Pantginis | $11 → $35 | Maintains | Buy | Get Alert |
| 05/18/2022 | LIFE | Buy Now | aTyr Pharma | $1.60 | 587.67% | Piper Sandler | Edward Tenthoff | $19 → $11 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for aTyr Pharma (LIFE)?
The latest price target for aTyr Pharma (NASDAQ: LIFE) was reported by RBC Capital on March 15, 2024. The analyst firm set a price target for $16.00 expecting LIFE to rise to within 12 months (a possible 900.25% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for aTyr Pharma (LIFE)?
The latest analyst rating for aTyr Pharma (NASDAQ: LIFE) was provided by RBC Capital, and aTyr Pharma maintained their outperform rating.
When was the last upgrade for aTyr Pharma (LIFE)?
There is no last upgrade for aTyr Pharma.
When was the last downgrade for aTyr Pharma (LIFE)?
The last downgrade for aTyr Pharma Inc happened on July 5, 2023 when Oppenheimer changed their price target from N/A to N/A for aTyr Pharma Inc.
When is the next analyst rating going to be posted or updated for aTyr Pharma (LIFE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of aTyr Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for aTyr Pharma was filed on March 15, 2024 so you should expect the next rating to be made available sometime around March 15, 2025.
Is the Analyst Rating aTyr Pharma (LIFE) correct?
While ratings are subjective and will change, the latest aTyr Pharma (LIFE) rating was a maintained with a price target of $19.00 to $16.00. The current price aTyr Pharma (LIFE) is trading at is $1.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.